Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 20, Number 7—July 2014
Research

Population-Based Analysis of Invasive Fungal Infections, France, 2001–2010

Dounia Bitar1, Olivier Lortholary1, Yann Le Strat, Javier Nicolau, Bruno Coignard, Pierre Tattevin, Didier Che2Comments to Author , and Françoise Dromer2
Author affiliations: Insitut de Veille Sanitaire, Saint Maurice, France (D. Bitar, Y. Le Strat, J. Nicolau, B. Coignard, D. Che); Institut Pasteur, Paris, France (O. Lortholary, F. Dromer); Centre National de la Recherche Scientifique, Paris (O. Lortholary, F. Dromer); Université Paris Descartes, Paris (O. Lortholary); CHUPontchaillou, Rennes, France (P. Tattevin)

Main Article

Table 1

Cases of invasive fungal infection and attributable deaths in metropolitan France by disease, sex, and age, 2001–2010*

Infections
 No. case-patients
 Male sex, %
 Age, y, median (IQR)
 Illness incidence (95% CI)†
 Fatality rate, % (95% CI)
Candidemia
Cases 15,559 58.8 64 (51–75) 2.5 (2.1–2.9)
Deaths
 6,217
 60.0
 69 (56–77)
40.0 (38.7–42.0)
Pneumocystis pneumonia
Cases 9,365 71.3 44 (37–55) 1.5 (1.2–1.9)
Deaths
 862
 71.9
 58 (43–70)
9.2 (7.6–12.4)
Invasive aspergillosis‡
Cases 8,563 63.9 58 (45–68) 1.4 (1.2–1.6)
Deaths
 2,443
 66.7
 61 (49–71)
28.5 (26.9–30.5)
Cryptococcosis‡
Cases 1,859 72.3 43 (36–55) 0.3 (0.2–0.4)
Deaths
 278
 73.4
 49 (39–65)
15.0 (13.2–17.9)
Mucormycosis‡
Cases 530 57.7 58 (43–71) 0.09 (0.07–0.1)
Deaths
 89
 62.9
 57 (44–67)
16.8 (11.3–20.2)
Total
Cases 35,876 64.0 56 (42–70) 5.9 (5.5–6.3)
Deaths
 9,889
 63.1
 65 (53–75)
27.6 (25.3–29.7)
*A total of 197 Candida-related endocarditis and 10 meningitis cases were excluded from analysis. IQR, interquartile range.
†Incidence expressed as number of cases per 100,000 population per year (averaged over 10 y)
‡Invasive aspergillosis includes 91.7% pulmonary and 8.3% disseminated cases. Cryptococcosis includes 63.8% cerebral or disseminated forms; 13.2% pulmonary, cutaneous, or bone localizations; and 23.0% unspecified; forms. Mucormycosis includes 50.9% pulmonary, rhinocerebral and disseminated forms; 16.9% cutaneous forms; and 32.1% unspecified forms.

Main Article

1These authors contributed equally to this article.

2These authors contributed equally to this article.

Page created: June 17, 2014
Page updated: June 17, 2014
Page reviewed: June 17, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external